A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that PEGylated liposomes (PEGLip) can shield
FVIII from the immune system and inhibitors, and therefore provide a prophylactic FVIII
replacement therapy for patients with inhibitors to FVIII.